Biodel (BIOD) +12.7% premarket after the biopharma company reported positive top-line results...

|By:, SA News Editor

Biodel (BIOD) +12.7% premarket after the biopharma company reported positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog candidates conducted to evaluate pharmacokinetic and injection site toleration profiles relative to Humalog, a rapid-acting insulin analog.